Positive Phase 2b dupilumab data in asthma announcedSanofi
Sincedupilumabhas only recently been registered for use in severe asthma, studies on clinical or functional characteristics predicting response are limited. In a post-hoc analysis of a phase 2b trial, patients with a history of > 1 exacerbation in the prior year or baselineFEV1≤ 1.75 L, showed...
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic...
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44. doi:10.1016/S...
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ran... Dupilumab, a fully human anti-interleukin-4 receptor α mo...
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40-52. doi:10.1016/S0140-6736(15)00388-8 PubMedGoogle ScholarCrossref...
Plain Language Summary Atopic dermatitis (AD) is a chronic skin disease that is relatively common in infants and young children worldwide. Severe AD causes skin rashes and intense itch that strongly interfere with sleep quality and normal daily activities, thereby affecting the quality of life of ...
pooled analysis (from 6 phase 3 studies (NCT03346434, NCT03345914, NCT03054428, NCT02260986, NCT02277743 and NCT02277769) assessing IgE levels in patients aged 6 months and older with moderate-to-severe AD presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and ...
The Phase 3 clinical trial of dupilumab lasting 16 to 52 weeks did not reveal an increased incidence of infectious disease [[36], [37], [38]]. A potential long-term inhibitory effect of IL-4R on the maintenance of naive B cell homeostasis and durable vaccination response is unknown. In...
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44. Article PubMed CAS ...